Overview

GSK573719 Dose Ranging Study in Chronic Obstructive Pulmonary Disease

Status:
Completed
Trial end date:
2010-03-15
Target enrollment:
Participant gender:
Summary
The study will evaluate the dose response, safety, and pharmacokinetics of GSK573719 compared with placebo in subjects with COPD.
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Tiotropium Bromide